Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma's lead product candidate, OC-01 (varenicline) nasal spray, a highly selective cholinergic agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. In pre-clinical and clinical studies, OC-01 (varenicline) nasal spray was shown to have a novel mechanism of action via activation of the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the lacrimal functional unit.
Company profile
Ticker
OYST
Exchange
Website
CEO
Jeffrey A. Nau
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
811030955
OYST stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
13 Jan 23
8-K/A
Termination of a Material Definitive Agreement
13 Jan 23
EFFECT
Notice of effectiveness
6 Jan 23
25-NSE
Exchange delisting
3 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Jan 23
POS AM
Prospectus update (post-effective amendment)
3 Jan 23
8-K
Termination of a Material Definitive Agreement
3 Jan 23
Transcripts
OYST
Earnings call transcript
2022 Q2
13 Aug 22
OYST
Earnings call transcript
2022 Q1
8 May 22
OYST
Earnings call transcript
2021 Q4
27 Feb 22
OYST
Earnings call transcript
2021 Q3
7 Nov 21
OYST
Earnings call transcript
2021 Q2
8 Aug 21
OYST
Earnings call transcript
2021 Q1
9 May 21
OYST
Earnings call transcript
2020 Q4
19 Feb 21
OYST
Earnings call transcript
2020 Q3
7 Nov 20
OYST
Earnings call transcript
2020 Q2
7 Aug 20
OYST
Earnings call transcript
2020 Q1
11 May 20
Latest ownership filings
SC 13G/A
Paradigm Biocapital Advisors LP
14 Feb 23
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 23
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 23
SC 13D/A
Versant Venture Capital VI, L.P.
13 Jan 23
SC 13D/A
New Enterprise Associates 14, L.P.
9 Jan 23
SC 13D/A
InvOpps IV US, L.P.
5 Jan 23
4
SACHA LAINOVIC
5 Jan 23
4
Change in insider ownership
4 Jan 23
4
Ali Behbahani
4 Jan 23
4
PATRICK J KERINS
4 Jan 23
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 68.80 mm | 68.80 mm | 68.80 mm | 68.80 mm | 68.80 mm | 68.80 mm |
Cash burn (monthly) | 12.05 mm | 9.62 mm | 11.30 mm | 13.20 mm | 11.99 mm | 13.83 mm |
Cash used (since last report) | 227.33 mm | 181.53 mm | 213.34 mm | 249.20 mm | 226.29 mm | 261.06 mm |
Cash remaining | -158.53 mm | -112.73 mm | -144.54 mm | -180.40 mm | -157.49 mm | -192.26 mm |
Runway (months of cash) | -13.2 | -11.7 | -12.8 | -13.7 | -13.1 | -13.9 |
Institutional ownership, Q1 2023
22.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 55 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 68.56 mm |
Total shares | 5.93 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
New Enterprise Associates 14 | 5.93 mm | $68.56 mm |
Versant Venture Capital VI | 0.00 | $0.00 |
InvOpps IV US | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 Jan 23 | Atieh Michael G | Common Stock | Sale back to company | Dispose D | No | No | 0 | 8,671 | 0.00 | 0 |
3 Jan 23 | Atieh Michael G | Common Stock | Dispose U | No | No | 0 | 18,063 | 0.00 | 8,671 | |
3 Jan 23 | Atieh Michael G | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 17.74 | 5,199 | 92.23 k | 0 |
3 Jan 23 | Atieh Michael G | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 3.63 | 5,359 | 19.45 k | 0 |
3 Jan 23 | George Christopher Eliades | Common Stock | Sale back to company | Dispose D | No | No | 0 | 16,863 | 0.00 | 0 |
3 Jan 23 | George Christopher Eliades | Common Stock | Sale back to company | Dispose D | No | No | 0 | 11,761 | 0.00 | 16,863 |
3 Jan 23 | George Christopher Eliades | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 17.74 | 5,199 | 92.23 k | 0 |
3 Jan 23 | George Christopher Eliades | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 3.63 | 5,359 | 19.45 k | 0 |
3 Jan 23 | Murray Mark Anthony | Common Stock | Sale back to company | Dispose D | No | No | 0 | 3,573 | 0.00 | 0 |
3 Jan 23 | Murray Mark Anthony | Common Stock | Sale back to company | Dispose D | No | No | 0 | 118,513 | 0.00 | 3,573 |